Reception
|
Lift
|
HTML version
Notice Board
News
Join the NPC New Medicines email discussion group
--------------------------------
NICE guidance on lipids recommends using the NPCi decision aid on statins
--------------------------------
Commissioning for Integrated Medicines Management Programme (CIMM) Participating Teams now available to view
--------------------------------
Discuss issues relating to medicines reconciliation in the new discussion room
--------------------------------
eCAB - the NPC's daily current awareness bulletin
--------------------------------
Sign up for a MyNPC account to subscribe to the full range of email services from the NPC
Events
Watch this space! More events coming soon.....
--------------------------------
Publications
MeReC Bulletin Volume 19 Number 3 December 2008 Lipid-modifying treatment
--------------------------------
MeReC Monthly No.9: Aspirin ineffective for primary prevention in patients with diabetes The CV risk of NSAIDs: final analysis of APPROVe Concomitant use of an SSRI and an NSAID increases the risk of upper GI bleeding Internet-based learning in
--------------------------------
MeReC Extra No. 36: Using patient decision aids What’s new from the National Prescribing Centre?
--------------------------------
MeReC Monthly No.8: Anticholinergics in COPD — new data on cardiovascular safety Navigating through SEAS and ezetimibe▼ — questions raised over cancer risk NICE issues guidance on ADHD
--------------------------------
Dispensing with Repeats: A practical guide to repeat dispensing (2nd edition, 2008)
Blog & Podcast
The NPCi Blog Homepage
--------------------------------
NPCi podcasts - Latest content uploaded 19th November 2008
--------------------------------
Meta-analysis demonstrates statins benefit on total mortality in primary prevention
--------------------------------
High-concentration capsaicin patch for the treatment of postherpetic neuralgia – more data needed
--------------------------------
Is one beta-blocker better than another in heart failure?
--------------------------------
Rivaroxaban (Xarelto®▼) reduces symptomatic VTE and death more than enoxaparin in patients undergoing hip or knee replacement
